Illustrative image.
Pomalyst
Pomalidomide
$26880.00
3mg · 4 × 21 capsules · 3 months supply
BrandBranded medicine
$8960.00 per month
Strength
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$114240a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
1mg
2mg
3mg
4mg
FDA boxed warningEmbryo-fetal toxicity and venous and arterial thromboembolism
EMBRYO-FETAL TOXICITY
POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects.
For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception.
POMALYST is available only through a restricted program called PS-Pomalidomide REMS.
VENOUS AND ARTERIAL THROMBOEMBOLISM
Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended.
About Pomalyst
Overview
Pomalyst contains pomalidomide, a medicine related to thalidomide, and comes as capsules. It is used with dexamethasone for adults with multiple myeloma who have received at least two previous treatments, including lenalidomide and a proteasome inhibitor, and whose disease worsened during or within 60 days after their last treatment. It also treats adults with AIDS-related Kaposi sarcoma after highly active antiretroviral therapy has failed, or Kaposi sarcoma in HIV-negative adults; this use has accelerated FDA approval based on response rates, with continued approval potentially depending on confirmatory trials. It works by affecting immune activity, acting against cancer cells and inhibiting the formation of new blood vessels.
What it treats
• Multiple myeloma in adults, used with dexamethasone after at least two prior therapies, including lenalidomide and a proteasome inhibitor, when the disease has progressed during or within 60 days after completing the last therapy. • Kaposi sarcoma in adults with AIDS after highly active antiretroviral therapy (HAART) has failed, or in adults who are HIV-negative. This indication has accelerated approval based on overall response rate; continued approval may depend on confirmatory trials verifying clinical benefit.
Safety information
Side effects
Common side effects include tiredness, weakness, constipation, nausea, diarrhea, shortness of breath, upper respiratory tract infections, back pain, fever and rash. Blood tests may show low white blood cells, including neutrophils, low red blood cells or hemoglobin, and low platelets. Other common test changes include increased creatinine, blood sugar or the liver enzyme ALT, and decreased phosphate, albumin or calcium. Which effects are most common varies by the condition being treated. Serious risks include blood clots in veins or arteries, harm to an unborn baby, severely reduced blood cell counts, liver damage or liver failure that can be fatal, severe skin reactions, and severe allergic reactions, including angioedema (swelling) and anaphylaxis. Seek urgent medical help for a severe allergic or skin reaction, or suspected blood clots. Contact your doctor promptly about dizziness, confusion or nerve problems. Other serious risks include new cancers and tumor lysis syndrome, a complication of rapid tumor breakdown. People with a high tumor burden need monitoring and precautions for tumor lysis syndrome. Your doctor will monitor blood cell counts and check liver function monthly. The label also warns of increased deaths in people with multiple myeloma when pembrolizumab was added to dexamethasone and a thalidomide analogue.
FDA boxed warning
Embryo-fetal toxicity and venous and arterial thromboembolism
EMBRYO-FETAL TOXICITY
POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects.
For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception.
POMALYST is available only through a restricted program called PS-Pomalidomide REMS.
VENOUS AND ARTERIAL THROMBOEMBOLISM
Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Pomalyst if you are pregnant or have hypersensitivity (an allergy) to the medicine. Do not breastfeed during treatment. Important precautions include: • Blood-related toxicity, especially neutropenia (low levels of a type of white blood cell), requires monitoring. • Liver failure, including fatal cases, has been reported. Liver function tests should be checked monthly. • Severe skin reactions require Pomalyst to be stopped. It must also be stopped if angioedema (swelling beneath the skin) or anaphylaxis (a severe allergic reaction) occurs. • Patients with a high tumour burden need monitoring and precautions for tumour lysis syndrome. • Increased mortality was observed in patients with multiple myeloma when pembrolizumab was added to dexamethasone and a thalidomide analogue.
Interactions
Avoid taking Pomalyst with medicines that strongly inhibit the enzyme CYP1A2. Ask your doctor whether any of your other medicines fall into this group. If combined use cannot be avoided, your prescriber will need to reduce your Pomalyst dose.
Using Pomalyst
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label POMALYST (POMALIDOMIDE) CAPSULE [CELGENE CORPORATION] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00